Over the last few years, Curetis has created a down-to-earth and continuous success story. It all began with the Unyvero product idea and progressed through the development and approval procedure towards tapping into the international medical technology markets. From the outset, the company has impressed with its high awareness of quality combined with a strong pioneering spirit and the simple claim: "We care for diagnostics". This success was due, in no small part, to the outstanding engineering capabilities and molecular and microbiological expertise of both our investors and our customers and partners.
Curetis' growth potential lies, on the one hand, in developing and expanding the world's national markets and, on the other hand, in extending the Unyvero system with a continuous stream of new cartridges for additional infectious diseases.
Curetis’ Unyvero Intra-Abdominal Infection (IAI) Cartridge Receives CE Marking
Curetis Reports Full-Year 2016 Financial Results and Updates 2017 Guidance
27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria - 22 to 25 April, 2017
ECCMID 2017 - VIENNA SATURDAY, 22ND APRIL 2017 | 13:30-15:30 H | HALL E
DETECT TO CURE – SUPERBUGS IN VARIOUS HEALTH CARE SETTINGS DIAGNOSTIC APPROACHES TO WIN THE CHALLENGE